Journals / Eurasian Journal of Emergency Medicine / 2016 / Cilt: 15 - Sayı: 4

Should We Routinely Screen for Warfarin Gene Polymorphism in Patients with Coumadin Overdose?

Pages
199–201
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the present case report, frequently occurring warfarin toxicity was caused by a genetic mutation in the patient with mitral valve replacement.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Genetic polymorphisms can affect an individual's response to the pharmacological agents.
📊
Key Findings & Data:An insufficient dose may fail to prevent thromboembolism and overdose may increase the risk of bleeding.
💡
Conclusion & Impact:In the present case report, frequently occurring warfarin toxicity was caused by a genetic mutation in the patient with mitral valve replacement.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Genetic polymorphisms can affect an individual's response to the pharmacological agents. Warfarin has a narrow therapeutic range and dose arrangement may vary from individual to individual. An insufficient dose may fail to prevent thromboembolism and overdose may increase the risk of bleeding. Increasing evidence suggests that genetic variation of CYP2C9 and VKORC1 greatly influences effective warfarin dosing (1). In the present case report, frequently occurring warfarin toxicity was caused by a genetic mutation in the patient with mitral valve replacement.

🔖

Cite This Article

GÜL, E. E., ERDOĞAN, H. İ., YAZICI, M. (2022). Should We Routinely Screen for Warfarin Gene Polymorphism in Patients with Coumadin Overdose?. Eurasian Journal of Emergency Medicine, Cilt: 15 - Sayı: 4, 199–201. https://ajindex.com/articles/508119

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. D'Andrea G, D'Ambrosio R, Margaglione M. Oral anticoagulants: pharma- cogenetics relationship between genetic and non-genetic factors. Blood Rev 2008; 22:127-40.
  2. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, sci- entific, and clinical issues. J Thromb Thrombolysis 2008; 25: 45-51. [CrossRef] Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res 2007; 120: 1-10. [CrossRef] Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Büller HR. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitiv- ity and bleeding risk. PLoS Med 2005; 2: e312. [CrossRef] Redman AR. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy 2001; 21: 235-42. [CrossRef] Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8. [CrossRef] Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005; 7: 97-104. [CrossRef] 201